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1. Introduction 
Gastroesophageal reflux disease (GERD) is a condition that develops when the reflux of 
stomach contents causes troublesome symptoms and/or complications (Vakil, et al , 2006a). 
GERD results from the combination of excessive gastroesophageal reflux of gastric juice and 
impaired esophageal clearance of the refluxate. The three dominant pathophysiologic 
mechanisms causing gastroesophageal junction incompetence are: transient lower 
esophageal sphincter relaxations (tLESRs), a hypotensive lower esophageal sphincter (LES), 
and anatomic disruption of the gastroesophageal junction, often associated with a hiatal 
hernia. The dominant mechanism varies as a function of disease severity with tLESRs 
predominating with mild disease and mechanisms associated LES dysfunction and hiatus 
hernia predominating with more severe disease (Bardham CP, et al, 1995). 
According to Montreal classification we divide GERD into esophageal and extraesophageal 
syndromes, with extraesophageal syndromes divided into established and proposed 
associations (Vakil,et al. 2006; figure 1,2).  
Esophageal 
Syndromes
Extra-esophageal
Syndromes
Symptomatic 
Syndromes
 Typical Reflux
Syndrome
Reflux Chest
Pain Syndrome
Syndromes with
Esophageal Injury
Reflux Esophagitis 
Reflux Stricture
Barrett’s Esophagus 
Adenocarcinoma
Established 
Associations
Reflux Cough 
Reflux Laryngitis
Reflux Asthma 
Reflux Dental Eros.
Proposed 
Associations
 Pharyngitis
 Sinusitis 
 Idiopathic
Pulmonary Fibrosis
Recurrent Otitis
Media
 
Fig. 1. Montreal classification of GERD 
The prevalence of GERD is the greatest in developed world from 10 % in UK and Spain to 29 
% in the USA (Dent, et al, 2005). Nonerosive reflux disease (NERD) is the most prevalent 
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form of GERD with prevalence between 50 % and 70 % (Johansson KE, et al 1986 ; Jones RH, 
et al.1995).According to Rome III. criteria NERD is further subdivided to thrue NERD and 
functional heartburn (Drossman D, 2006; figure 2). 
 
Fig. 2. Diagnostic algorithm for NERD 
With medical therapy we can act on the acidity of refluxat (proton pump inhibitors – PPI, 
H2 blockers, antacids) or with surgery on mechanical reasons for reflux (laparascopic or 
open surgical technics). At the moment we don’t have medicines in routine clinical practice 
that can correct the basic reasons for pathologic gastric reflux into the esophagus. In this 
chapter I would like to address some questions about GERD therapy in different subtypes of 
GERD and in some specific conditions (gravidity) as well as about long term therapy of 
GERD and potential side effects of long term PPI therapy. 
2. GERD therapy 
In the medical management of GERD we can use a "step up" approach (beginning with 
lifestyle and dietary measures and increasing the treatment from antacids to H 2 blockers 
and finally to proton pump inhibitors or a "step down" approach (beginning with potent 
antisecretory agents- PPIs to achieve rapid symptom control and then incrementally 
decreasing the intervention until patients remain in remission). 
We always have to inform patients about necessary lifestyle modifications and about use of 
antacids and alginates for acid breakthrough symptoms. PPIs are the therapy of choice for 
GERD patients. 
2.1 Lifestyle modifications 
GERD is a chronic disease with frequent relapses. Patients should be informed about 
preventive measures – lifestyle modifications that can have an important influence on their 
GERD symptoms (Kahrilas, et al, 2008).  
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Head of bed elevation for 6-8 inches is important for individuals with nocturnal or 
Extraesophageal syndromes. Patients should refrain from assuming a supine position after 
meals and avoid having meals three hours before bedtime, both of which will minimize 
reflux. Obesity is a risk factor for GERD, erosive esophagitis, and esophageal 
adenocarcinoma. However, improvement in symptoms following weight loss is not 
uniform. Nevertheless, because of a possible benefit, and because of its other positive effects 
on human health , weight loss should be recommended (Hampel H, et al, 2005). Patients 
should be informed that alcohol use and smoking should be stopped, because of its harmful 
effect on mucosa and because smoking diminishes salivation. 
Other measures includes avoidance of reflux-inducing foods (fatty foods, chocolate, 
peppermint, and excessive alcohol) which may reduce lower esophageal sphincter pressure. 
Patient should selectively avoid food known to cause symptoms like colas, red wine, and 
orange juice (pH 2.5 to 3.9).  
A systematic review of the articles published on lifestyle modification concluded that at the 
moment, data support only positive impact of weight loss and head of bed elevation. 
(Kaltenbach T, et al , 2006). 
2.2 Medical therapy of GERD and NERD  
The severity of symptoms does not correlate with the presence or with severity of subtypes 
of GERD (Smout AJPM, 1997). 
Treatment of GERD should aime at the relief of symptoms and healing of mucosal injury. 
There is no difference in therapeutic approach to erosive esophagitis (ERD) or nonerosive 
esophagitis (NERD) patients. 
Antacides and alginate antacids provide only temporal benefit and are ineffective in healing 
of esophageal mucosal injury. They can be used alone only in case of infrequent 
postprandial symptoms. 
Prokinetic drugs enhance gastrointestinal motility. These drugs can theoretically be useful 
adjuncts in the treatment of GERD by increasing lower esophageal sphincter pressure, 
enhancing gastric emptying, or improving peristalsis.They can be used only in some special 
circumstances: in case of delayed gastric emptying or duodenogastroesophageal reflux 
(Kahrilas PJ,et al,2008). 
H 2 receptor antagonists (H 2 blockers) inhibit acid secretion by blocking histamine H 2 
receptors on the parietal cell. H 2 blockers heal 52 % of patients with esophagitis compared 
to 8% with placebo. (NNT is 5 for H2 blockers compared to placebo in healing of GERD) 
(Khan M , et al 2007, Moayyedi P & Talley NJ, 2006).The problem of H 2 blockers is 
tachyphylaxis (reduction in therapeutic effect) after one week of therapy. The therapeutic 
effect of H2 blockers drop to approximately 50 % after 7 days of therapy (Sachs et al 2006). 
Proton pump inhibitors (PPIs) are prodrugs which are activated in the stomach by a two 
step process. First step is conversion of PPI to its sulfenamide derivative and in the second 
step sulfenamid is protonated to benzimidazole , which binds irreversible to the H/K 
ATPase. That blocks the H/K ecxhange and prevent parietal cell from producing acid. PPIs 
concentrate in the parietal cell secretory canaliculus , where pH is approximately 1,0 (the 
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second step in PPI activation needs pKa close to 1). Renal medulla and resorbtive surface of 
bone (osteoclasts have proton pump) do not have a low pH enough to permit the second 
step of PPI activation. Elsewhere in the body PPIs follow first-order kinetics. Blood levels of 
PPIs decrease as the drugs are metabolized in the liver and then excreted primarily in the 
urine or stool (Shi S&Klotz U, 2008, Shin JM,&Sachs G, 2008, Sachs G, et al. 1995, Sachs G, et 
al 2006). 
We have several PPIs with different daily doses recomended by manufacturer (table 1) NNT 
is 2 for PPI compared to placebo in healing of GERD (Khan M , et al 2007, Moayyedi P & 
Talley NJ, 2006). 
 Delayed release:                   Omeprazole 20 mg qd
Lansoprazole 30 mg qd
Rabeprazole 20 mg qd
Pantoprazole 40 mg qd
Esomeprazole 40 mg qd
 Immediate release:      Omeprazole + bicarbonate 40 mg qd
 Dual delayed release:          Dexlansoprazole 60 md qd
 
Table 1. Different Proton pump inhibitors and recommended daily doses 
PPIs inhibit only active pumps. A single dose of a PPI does not inhibit all pumps and does 
not result in profound inhibition of acid secretion. Acid production is inhibited with 
subsequent PPI doses, taking 5–7 days to achieve a steady state. Acid inhibition is never 
complete because of continued synthesis of new proton pumps. When PPIs are given twice 
daily, more active proton pumps are exposed to drug, and steady-state inhibition of gastric 
acid secretion is achieved more rapidly and more complete (Bell NJV, et al 1992).  
PPIs are usually prescribed once daily, usually in the morning. Food affects the 
bioavailability of each molecule, so it is our practice to recommend that all PPIs should be 
given prior to meals for optimal efficacy. Results of intragastric pH studies showed that 
superior daytime pH control (time intragastric pH>4) was seen when the PPI was taken 
before breakfast compared to after meal. PPIs are responsible for inhibiting gastric acid 
secretion, thereby decreasing potential damage to the esophageal mucosa. In addition, by 
raising gastric pH, the conversion of pepsinogen to pepsin, another player of mucosal 
damage, is inhibited. (Hatlebakk JG,et al , 2000).  
In a large meta analysis of 136 randomized controlled trials involving 35 978 patients with 
esophagitis, the healing rate among those patients treated with PPIs was 83 %. In all trials 
antacids were used to treat breakthrough symptoms. There were no major differences in 
efficacy among standard dose of various PPI.  
PPIs are better in healing erosive esophagitis than in controlling GERD symptoms. In a large 
patient unmeat needs survey, patients on PPIs reported the highest level of satisfaction (57,9 
%) , followed by H-2 blockers (46,1 %; Crawley MS&Schmitt CM, 2000). 
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FDA approved dosing of PPIs in GERD patients is once daily. In our daily practice we know 
that substantial number of patients (32 %) on once daily PPI continue to demonstrate 
abnormal distal esophageal acid exposure and this proportion can be lowered to less than 10 
% by increasing standard therapy of PPI to BID (Charbel S, et al , 2006). There is no 
supporting data for the use of nocturnal dose of a H 2 blocker to twice daily PPI therapy 
(Vakil N, et al , 2006b). Dosing a PPI before dinner is significantly more effective for 
nocturnal acid control than dosing before breakfast (Hatlebakk JG,et al, 1998) .The American 
College of Gastroenterology currently recommends dosing PPIs before evening meal if 
nighttime acid controlled is needed (DeVault KR& Castell DO , 2005) Because of the short 
plasma half-life of the PPIs, loss of nocturnal acid control occurs approximately 7 hours after 
evening dose (Peghini PL,et al 1998). 
Patients with GERD (erosive or nonerosive) should be treated with standard dose of PPIs for 
at least 2-3 months. 
The proportion of NERD patients responding to a standard dose of PPI is approximately 20-
30% lower than what has been documented in patients with erosive esophagitis. In a 
systematic review of the literature, PPI symptomatic response pooled rate was 36.7% (95% 
CI: 34.1-39.3) in NERD patients and 55.5% (95% CI: 51.5-59.5) in those with erosive 
esophagitis.(Dean BB , et al , 2004). The greater the distal esophageal acid exposure, the 
higher the proportion of NERD patients reporting symptom resolution.(Lind T, et al, 1997) 
Patients with NERD also demonstrate longer lag time to sustained symptom response when 
compared to patients with erosive esophagitis (2 to 3-fold). Furthermore, patients with 
NERD demonstrate similar symptomatic response to half and full standard dose of PPI, 
unlike patients with erosive esophagitis who demonstrate an incremental increase in healing 
and symptom resolution with standard dose compared to half dose of PPIs (Richter JE,et al , 
2000). The reason for the differences in therapeutic response between NERD and erosive 
esophagitis is primarily due to the common inclusion of functional heartburn subjects in the 
NERD group. However, because most NERD patients demonstrate only modest abnormal 
esophageal acid exposure, even after excluding functional heartburn patients, the NERD 
symptomatic response rate to PPI remains lower that what has been observed in erosive 
esophagitis patients (Hershovici T & Fas R, 2010). 
The most common side effects of proton-pump inhibitors are headache, diarrhea, 
constipation, and abdominal pain. Although in clinical trials these symptoms were not 
significantly more common with proton-pump inhibitors than with placebo, they have been 
confirmed in some patients with a test–retest strategy. 
2.3 GERD and pregnancy  
The smooth muscle relaxation as well as the increased intraabdominal pressure that occurs 
during pregnancy predisposes to gastroesophageal reflux (Katz PO& Castell DO, 1998). The 
greatest experience with pharmacologic acid-suppressive therapy in pregnant women has 
been with the H2 receptor antagonists ranitidine and cimetidine, which appear to be safe 
during pregnancy (Larson JD, et al, 1997). There is less experience using proton pump 
inhibitors during pregnancy, but they are probably safe. A meta-analysis of seven studies 
(involving a total of 1530 exposed and 133,410 non-exposed pregnant women) found no 
significant difference in the risk for major congenital birth defects, spontaneous abortions, or 
preterm delivery (Gill SK,et al, 2009). 
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2.4 Medical therapy of extraesophageal syndromes  
Astma, cronic cough, laryngitis and non cardial chest pain (esophageal syndrome) are 
among the conditions where an association with GERD is well established. On the other side 
GERD can be just one of possible ethiologic factors for that diseases. The causal relationship 
of GERD with with this nonspecific syndromes in absence of a concomitant esophageal 
GERD syndrome remains controversial and unproven. 
In the pro-GERD study that included 6215 patients in Europe 34,9 % of patients with GERD 
and 30,5 % of patients with NERD have some Extraesophageal Syndromes (Jaspersen D, et 
al. 2003). 
In patients with chronic cough, asthma and laryngeal symptoms PPI standard dose BID is 
usally prescribed. With this approach likelihood of normalizing esophageal acid exexposure 
is 93% - 99 % (Charbel S, et al, 2005). Therapy is usually prescribed for 3 months. Studies to 
support this approach are open label and uncontrolled (Kahrilas Pa, et al, 2008; Tepeš B, 
2006). Patients with extraesophageal syndromes can be treated with PPIs only if 
concomitant esophageal GERD syndrome is present. 
2.5 NCCP 
Chest pain indistinguishable from ischemic cardiac pain can be caused by GERD – noncardiac 
chest pain / NCCP (Vakil, et al, 2006a). Community prevalence rates of NCCP are from 23% to 
33% (Locke GR, et al, 1997; Eslick GD, et al, 2003). In patients with chest pain ischemic heart 
disease must be excluded first, GERD is the next most likely pathology. PPIs BID for 8 weeks 
are recommended in patients with NCCP.Those patients with a good therapeutic response 
need maintenance therapy with PPIs. If patients do not response to PPIs manomety testing is 
necessary and specific therapy for motility disorders if proven are needed. 
2.6 Maintenance therapy of GERD 
Patients with erosive esophagitis have up to 80 % chance of recurrence within 12 months of 
treatment discontinuation (Johnson DA, et al, 2001; Vakil NB, et al, 2001). GERD recurrence 
is dramatically decreased by PPI treatment (Donnellan C, et al, 2005, Tepeš , et al, 2009). A 
systematic review of 17 studies (15 of which were randomized controlled trials) showed that 
subjects with either nonerosive or uninvestigated GERD did well with on-demand regimens 
(Pace F, et al, 2007). In study where patients with known erosive esophagitis after being 
healed with PPI therapy were randomized to either continuous or on-demand therapy, 
recurrence of erosive disease was higher in subjects treated with on-demand compared 
continuous therapy (42% vs 19% at 6 months; P <.00001). On-demand therapy cannot be 
recommended for maintaining healing of erosive esophagitis (Sjostedt S, et al ,2005).  
In our experience patients with GERD LA C and LA D need standard PPI dose or even 
higher dose as a maintenance therapy, patients with GERD LA B need standard dose of PPI 
and in those with GERD A can be put on half a standard dose of PPI (Figure 3,4 Tepeš, et al 
2009). 
Maintenance therapy should be prescribed to all patients with Barrett oesophagus. Some 
uncontrolled studies showed that PPI therapy can in part prevent progression of Barrett 
esophagus to dysplasia and adenocarcinoma (El Serag HB, et al, 2004). 
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Recommendations regarding maintenance therapy in group of patients with 
Extraesophageal syndromes are based on expert opinion , because we do not have data from 
prospective control trials. Step-down therapy should be attempted in all patients with 
extraesophageal reflux syndromes after empirical twice-daily three months PPI therapy. 
Continuing maintenance PPI therapy should be predicated on either the requirements of 
therapy for concomitant esophageal GERD syndromes or extraesophageal syndrome 
symptoms. In both cases, maintenance therapy should be with the lowest PPI dose 
necessary (Kahrilas PJ, et al, 2008) . 
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Fig. 3. Cumulative percent of patients in remission in group A2 (omeprazole 10 mg daily) at 
3, 6, 9, and 12 months of maintenance therapy by baseline number of patients with a specific 
grade of disease (intention-to-treat, ITT) 
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Fig. 4. Cumulative percent of patients with esophagitis grade A in remission in groups A1 
(omeprazole 20 mg on demand) and A2 (omeprazole 10 mg QID) at 3, 6, 9, and 12 months of 
maintenance therapy by number of patients with esophagitis grade A concluding the study 
in these groups (per-protocol) 
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2.7 PPI refractory GERD 
Patient with GERD are named refractory to PPIs when they do not respond to PPI standard 
dose BID . Potential etiologies may be gastrointestinal (GI) or non-GI related. The GI 
etiologies can be esophageal or nonesophageal, and the former may be reflux or nonreflux 
related.  
There are 3 major categories of reflux related causes: 
1. First category is reflux with ongoing acid exposure. Etiologies include incorrect 
medication dose timing, medication noncompliance, residual pathologic acid secretion, 
rapid PPI metabolism, a hypersecretory state, a significant anatomic abnormality like a 
large hiatal hernia, excess reflux during tLESRs, or defective esophageal mucosal 
barrier function.  
2. Second category is reflux of nonacid material from either the stomach or the duodenum 
(e.g., bile).  
3. Third category is reflux of normal amounts of weakly acidic or alkaline contents into a 
hypersensitive esophagus.  
The non-reflux–related esophageal causes include dysmotility syndromes such as achalasia, 
esophageal spasm, or scleroderma; eosinophilic esophagitis; pill esophagitis; and infectious 
esophagitis. 
In the absence of structural, motility, or inflammatory causes, functional heartburn or 
function chest pain should be considered. 
Nonesophageal causes of reflux-type symptoms include gallbladder disease, malignancy in 
the GI system or surrounding organs, cardiovascular disease, and musculoskeletal disease 
(Dellon ES & Shaheen NJ, 2010). 
After we are sure that patient adheres to the treatment recommendations and PPIs are 
prescribed BID, further diagnostic procedures are necessary. It is beyond the scope of this 
Chapter to discuss this procedures in more detail.  
2.8 Surgery and GERD  
Surgery is a therapeutic option in patients with GERD if GERD has been objectively 
confirmed. Surgery is an option in individuals who: 
1. Have failed medical management (inadequate symptom control, several regurgitation 
in case of big hiatal hernias, medication side effects. 
2. Do not to want to be on life long PPI treatment. 
3. Have extraesohageal GERD syndrome (asthma, hoarseness, chronic cough, NCCP, 
aspiration) and have a positive response to PPI therapy. 
Preoperatively workup includes: esophagogastroduodenoscopy, pH-metry, esophageal 
manometry, barium swallow. Patient should be operated in high volume centers with 
experiences in GERD laparoscopic surgery. The Nissen fundoplication has, in many series, 
been found superior to other procedures, with symptomatic improvement occurring in 85 % 
to 90 % of patients. This procedure originally involved passage of the gastric fundus behind 
the esophagus to encircle the distal 6 cm of the esophagus. Most surgeons choose to perform 
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a loose ("floppy") Nissen fundic wrap that is about 1 to 2 cm in length including a posterior 
crural repair. (Ellis FH Jr, 1992). In patients with weak propulsive peristalsis a parcial 
fundoplication is recommended (anterior fundoplication, Toupet parcial posterior 
fundoplication).  
Up to 20 % of patients will have postoperative dysphagia or gas-bloat syndrome and up 
to 10 % will need revisional surgery after laparoscopic fundoplication (Lamb PJ,et al. 
2009). 
Several randomized controlled trials have compared surgical therapy with medical therapy 
with a follow-up from 1 to 10,6 years. The majority of studies showed that patients need 
PPIs after operation in up to 21 % of cases, one study showed that this percentage is much 
higher -62 % (Spechler SJ, et al, 2001; Dassinger MS,et al, 2004; Kamolz T, et al. 2005; 
Zaninotto G,et al, 2007).  
There has been some randomized controlled trials evaluating cost between medical 
(omeprazole) and surgical therapy (open total and partial fundoplication) over a period up 
to 10 years. One modeling study found that the cost-equivalency point for medical and 
surgical therapy was at 10 years (Heudebert GR, et al, 1997) , whereas another still reported 
lower cost with medical therapy at 10 years (Arguedas MR, e tal, 2004). 
Barrett’s esophagus is present in 1.65% of the general population, in 8.6% of symptomatic 
GERD patients presenting to a tertiary care center, and in 10.8% of patients undergoing 
antireflux surgery . Barrett’s esophagus (neoplasia not present) is associated with a 
significantly increased risk for developing esophageal adenocarcinoma (approximately 100-
fold) over that of the general population (Ronkainen J, et al, 2005; Rex DK, et al, 2003, 
Attwood SE, et al, 2008). Antireflux surgery does not alter the need for continued 
surveillance endoscopy in patients with Barrett's esophagus. The available evidence is 
inconclusive about the effect of antireflux surgery on patients with Barrett's esophagus. 
3. Side effects of long term PPI therapy  
The risk of minor adverse effects from proton pump inhibitors use is 1%-3%, with rates of 
withdrawal from clinical research studies being 1%-2%, with no significant differences 
noted between the PPIs (Langtry HD,&Wilde MI, 1997; Laine L, et al 2000).The most 
common side effects of PPI therapy are: headache, diarrhea and abdominal pain with 
frequency up to 4 %, what is less than in H 2 blockers (Relly JP, 1999). 
Serious adverse effects are rare. Acute interstitial nephritis is a rare complication of PPI 
treatment (a class effect) which can be potentially reversible if we think on it early enough. 
Otherways it can lead to acute renal failure. PPIs' metabolites most probably act as a hapten 
in an autoimmune process in renal interstitium (Geevasinga N, 2006). Hepatitis or disrupted 
visual disturbances are very rare adverse effect of PPI use (Koury SI, et al ,1998; Garcia 
Rodriges LA,et al 1996). 
PPI are very frequent used as a maintenance therapy in some indications listed above. They 
are also very frequently used without proper indication, what can be a reason for mayor 
concern. Up to 60 % of PPI prescriptions, especially in primary care, are without appropriate 
indications (Nardino RJ, et al, 2000 ;Batuwitage BT, et al, 2007).  
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Long term PPI use can have influence on human physiology in different ways: 
1. long term hypochlorhydria can influence Ca, Fe, Mg, Vit B12 absorbtion, and can 
increase risk for enteric infections 
2. hypergastrinemia can have an effect on parathyroid gland, enterochromaffin cells, or 
gastric histology 
3. interactions with other drugs through cytochrome P450 
4. idiosyncratic effects 
3.1 Effects of PPIs on absorbtion of minerals and vitamins 
Clacium - Calcium solubility is important for its absorbtion . Acid facilitates release of 
ionized calcium from insoluble calcium salts (Nordin BE, 1997; Sheikh MS, et al 2007). 
Several studies have tried to evaluate the importance of acid for calcium absorbtion . Four 
out of five studies found decreased absorbtion of calcium in older patients on PPI therapy 
(Graziani G, et al, 1995; Graziani G, et al, 2002 ; Hardy P, et al, 1998 O'Connell MB,et al, 2005; 
Serfaty-Lacrosniere C, et al ,1995).  
Iron- Nonheme iron is a mayor source of dietary iron and is predominantly in the form of 
ferric iron. Iron absorbtion is directly related to the capacity of gastric juice to release iron 
contained in food (Chorad ME& Shade SG , 1968; Bezwoda W, et al, 1978). 
In a group of patients with Zollinger Ellison syndrome on long term PPI therapy for an 
everage of 6 years, no association was found with decreased stores of body iron or iron 
deficiency (Stewart CA, et al 1998). 
Magnesium – several cases of hypomagnesaemia were associated with long term PPI 
treatment. Prompt resolution of normal magnesium concentration occurred in two weeks 
after PPI discontinuation or switch to H2 receptor antagonist . The pathophysiologic 
mechanism for magnesium deficiency is not understood (Epstein M, et al, 2006; Cuny T & 
Disdsanayake A, 2008;). 
Vitamin B 12- gastric acid and pepsin release vit B12 from protein in food and allows vit 
B12 to bind to R protein and to intrinsic factor in duodenum (Doscherholmen A& Swaim 
WR, 1973; Festen HP, 1991). The majority of studies did not find that longterm PPI use 
reduce the vitamin B12 reabsorbtion. Only in the study which included older patients with 
Zollinger Ellison syndrome, vitamin B 12 serum concentration was significantly reduced. 
(Schenk BE ,et al, 1999; Insogna KL ,2009; McColl KE , 2009;). 
3.2 Effect on bone metabolism 
Long term PPI therapy can affect bone metabolism and cause osteoporosis through three 
potential mechanisms:  
- calcium absorbtion,  
- hypergastrinemia  
- vitamin B12 deficiency.  
The effect of PPI therapy on calcium metabolism has been already described. 
Hypergastrinemia can led to parathyroid hyperplasia which can increase bone resorbtion 
and reduce cortical bone mineral density, but clinical data are limited. (Mizunashi K,,et al , 
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1993). Vitamin B12 is involved in osteoblast activity and bone formation. Patients with 
marginally low levels of vitamine B12 were 4,5 fold more likely to have osteoporosis than 
dose with normal levels (Stone KL , et al, 2004; Tucker KL; Dhonukshe-Rutten RA , et al, 2003). 
Vitamin B12 deficiency can lead to neurologic complications that can also increase the risk of 
falls (Sato Y, et al, 2005).  
Several epidemiologic studies on the use of PPIs and risk for osteoporotic hip fractures have 
been published. A population based study using UK general practice research database (UK 
GPRD) observed a 44 % increased risk for hip fractures among patients older than 50 years 
on PPIs , with significant dose- and duration- response effects (Yang YX, et al, 2006). A 
population based study from Canada (Targownik LE, et al, 2008) associated long-term PPI 
exposure with a significant increase in risk of osteoporotic fractures (> 7 years of PPI 
exposure: OR, 1.92; 95% CI,1.16 –3.18; hip fractures > 7 years of PPI exposure: OR, 4.55; 95% 
CI, 1.68 –12.29).The problem of retrospective studies is bias due to confounding. In the 
nested case control studies using UK GPRD , Kaye et al did not find increased risk of 
fractures in patients on PPI therapy. Factors such as osteoporosis, vitamin B12 deficiency 
and prior fractures were among the leading reasons for exclusion , what makes it difficult to 
generalize the findings (Kaye JA & Jick H. 2008). Targownik et al conducted a cross-sectional 
and longitudinal analysis of patients referred for dual-energy X-ray absorptiometry scan . 
They did not associate PPI therapy with prevalent osteoporosis or with significant decreases 
in BMD over time (Targownik LE, et al, 2010). 
3.3 PPIs and infection 
Gastric acid acts as a barrier that keeps bacteria from colonizing the upper gastrointestinal 
tract. The increased bacterial colonization of the stomach observed in PPI users might be 
associated with pulmonary micro aspiration (Laheij RJ , et al, 2004; Theisen J, et al, 2000). 
Two retrospective studies found an increased risk for community- acquired pneumonia 
with current use of PPI (Laheij RJ , et al, 2004; Gulmez SE , et al, 2007). Both studies observed 
an inverse relationship between the magnitude of the association and the duration of PPI 
exposure. The weakest association was observed among current users who used the drug 
for the shortest duration. A third study conducted using the UK GPRD did not find an 
association between current use of PPIs and a significant increase in risk of community-
acquired pneumonia. (Sarkar M , et al, 2007) This study accounted for several highly 
influential confounders that were not considered in the previous studies. It also showed the 
inverse relationship between duration of current PPI therapy and risk of pneumonia by 
demonstrating the greatest increase in risk of community-acquired pneumonia in 
individuals who were issued a new PPI prescription in the past 48 hours. A similar pattern 
of risk increase was observed with H2RAs. These observations are inconsistent with a causal 
association mediated by acid suppression or immunosuppression. In fact, they indicate a 
protopathic bias (ie, drugs given to relieve early symptoms might be temporally associated 
with the subsequent illness).  
Several studies and a meta analysis by Leonard have observed a 2 to 3 fold increase in the 
risk of nosocomial or community associated Clostridium difficile or other enteric infections 
in patients on PPI therapy (Leonard J , et al, 2007; Wilcox MH , et al, 2008; Elphick DA, et al, 
2005). All the studies are retrospective and some have small number of patients included.  
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At the moment no PPIs given as once-daily dose truly increase gastric pH >4 for more than 
15 hours per day. A large randomized control trials are needed before PPIs can be blamed 
for increased infection risk.  
3.4 PPIs and gastric mucosa 
Fundic gland polys can appear after long term PPI therapy. Patients on PPIs have fourfold 
increased incidence of fundic glands polyps, which have no malignant potential (El-Zimaity 
HM , et al 1997; Raghunath AS , et al, 2005;). 
If a patients on PPI therapy have Helicobacter pylori (H pylori) infection, antrum 
predominant inflammatory phenotype can change to corpus predominant, what can 
accelerate atrophy and intestinal metaplasia. (Uemura N , et al, 2000). The first Maastricht 
Consensus recommended H pylori eradication in all GERD patients before they are 
enmbarked to PPI maintenance therapy (EHPSG, 1997). 
H pylori eradication may cause regression of gastric atrophy or intestinal metaplasia (Tepeš 
B , et al 1999; Sung JJ , et al 2000; Rocco A , et al , 2002; Ito M & Haruma K, 2002).  
Mild / modest hypergastrinemia is a physiologic response to reduction in acid secretion due 
to PPI therapy. Diffuse linear or micronodular hyperplasia of enterochromaffin like cells is 
observed in 10 % to 30 % of patients on chronic PPI therapy, mainly in H pylori positive 
patients. Dysplasia or carcinoid have never been described in long term PPI users (Solcia E , 
et al, 1992; Genta RM, et al, 2003). 
Gastrin has trophic effect on tissues through the gastrointestinal tract (Wang TC , et al, 
1996). In several studies no increase in colorectal polyps or cancer have been noticed in 
patients on maitennance PPI therapy (Robertson DJ, et al, 2007; Singh M,,et al, 2007; Van 
Soest EM, et al, 2008). 
3.5 PPIs and clopidogrel 
PPIs are metabolized by hepatic cytochrome P 450 system, predominantly by CYP2C19, and 
to lesser extent by CYP3A4 (Ishiazaki T& Horai Y, 1999). Clopidogrel is a pro-drug 
converted to an active metabolite by cytochrome P450 CYP2C19. Clopidogrel active 
metabolite irreversibly binds to the platel adenosine diphosphate P2Y receptor and inhibits 
platelet aggregation (Gurbel PA,et al, 2009). The common metabolic pathway can 
theoretically be a reason for drug-drug interaction that can have an impact on clopidogrel 
activity.  
The OCLA study first showed that omeprazole significantly decreased clopidogrel 
inhibitory effect on platel P2Y12 as assessed by VASP phosphorilation test (Gilard M , et al, 
2008). In in vitro study Di Angiolillo found that metabolic drug-drug interaction exists 
between clopidogrel and omeprazole but not between clopidogrel and pantoprazole 
(Angiolillo DJ,et al, 2011). 
Several retrospective studies pointed out that concomitant use of PPI and clopidogrel may 
be associated with adverse cerebrovascular events and myocardial infarction (Gupta E, et al, 
2009; Ho PM, et al, 2009; Juurlink DN, et al, 2009; Pezalla E, et al, 2008; Rassen JA, et al, 
2009). Meta analysis of 13 studies by Kwork showed no significant association between PPI 
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use and clopidogrel and overall cerebrovascular or cardiovascular mortality (Kwork CS, et 
al, 2010). 
The only two randomized prospective clinical trials, Triton TIMI 38 and Cogent 
(O’Donoghue ML, et al, 2009; Bhatt DL, et al, 2010) did not find any association between PPI 
use and risk of cerebrovascular or cardiovascular morbidity or mortality. Cogent data 
indicated that use of omeprazole with clopidogrel reduced the risk of gastrointestinal events 
compared with clopidogrel plus placebo, without increasing the risk of cardiovascular 
events. 
4. Conclusions 
PPIs are the therapy of choice for GERD patients. Ussually PPIs are prescribed QID for two 
to three months. One third of patients will need PPI BID. All GERD patients with 
Extraesophageal syndromes will need PPI BID for three to six months. Patients should be 
informed about lifestyle modifications and use of antacids for acid breakthrough.Those 
patients with ERD, Extraesophageal syndromes and Barrett esophagus need maintenance 
treatment with the lowest dose of PPI that keep them in remission.  
Surgery is a therapeutic option for patients who do not have complete therapeutic response 
with PPI therapy, who do not want to take PPIs lifelong or for those with proven GERD and 
Extraesophageal syndromes. Long term therapy can have some side effects especially on 
bone metabolism and can increase risk of enteric infections. The majority of long term side 
effects data are from epidemiologic or retrospective studies. To be able to clearly answer 
those questions we need prospective randomized controlled studies. 
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